Royalty Rate Set In Boston, Cordis Stent Spat
Resolving all remaining issues in a seven-year dispute over stent patents, a federal judge has ruled that Boston Scientific Corp. must pay a 5.1 percent royalty rate on its sales of...To view the full article, register now.
Already a subscriber? Click here to view full article